Document 0622
 DOCN  M9620622
 TI    [Effect of interferon alpha on immunologic parameters in patients with
       carcinoma of the renal parenchyma]
 DT    9602
 AU    Markinovic M; Jelic S; Milosevic D; Kovcin V; Spuzic I; Institute of
       Oncology and Radiology, Beograd.
 SO    Glas Srp Akad Nauka [Med]. 1994;(44):101-8. Unique Identifier : AIDSLINE
       MED/96021699
 AB    A wide range of immunological abnormalities have been described in
       renal-cell carcinoma (RCC). The only constant one was the decrease of
       CD4/CD8 ratio, reversible following radical nephrectomy in the absence
       of metastases. Alpha-interferon was administered with variable benefit
       to patients with metastatic RCC. The aim of this study was to document
       whether the treatment of patients with metastatic RCC, with unpurified
       human alpha-interferon, induced any change in the number and functional
       properties of peripheral blood T lymphocytes and monocytes. Fifteen
       patients were included in the study; all were treated with IFN 2,000,000
       IJ/24h x 15 days, with an intercycle interval of 15 days during at least
       4 cycles. The immunological analyses included the percentage and
       absolute number of E-rosette forming cells, CD3+, CD4+, CD8+ and CD4/CD8
       ratio as well as the percentage and absolute number of monocytes and
       their phagocytic index toward the yeast particles. The analyses were
       done before the treatment and after the 4th cycle of the IFN therapy and
       compared toward the same analyses done in 22 healthy controls. Following
       IFN treatment two significant changes were noted: a decrease in CD4/CD8
       ratio (mean 1.050 fall for 19% to 44%, mean 27.25% from the initial
       value) as well as a marked decrease in monocyte phagocytic index (p <
       0.005). These data point to either disease-related or treatment-related
       decrease in the phagocytic properties of monocytes and the decrease of
       CD4/CD8 ratio.
 DE    Carcinoma, Renal Cell/*IMMUNOLOGY/*SECONDARY/THERAPY  CD4-CD8 Ratio
       English Abstract  Human  Interferon-alpha/*THERAPEUTIC USE  Kidney
       Neoplasms/IMMUNOLOGY/*PATHOLOGY  Phagocytosis  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).